3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neuroblastoma
4
Multiple Myeloma
2
Vaccinia
1
Transplant-Related Hematologic Malignancy
1
Recurrence
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Hodgkin Disease
1
Glioma
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
9
Specimen Handling
7
X-Rays
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
5
Temozolomide
4
Biopsy
4
Vincristine
3
Cyclophosphamide
3
Cisplatin
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
pembrolizumab
2
palbociclib
2
olaparib
2
lutetium Lu 177 dotatate
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Radiotherapy
2
Radiation
2
Platinum
2
Lomustine
2
LY3023414
2
Diphtheria-Tetanus Vaccine
2
1,2-diaminocyclohexaneplatinum II citrate
2
sodium thiosulfate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Medulloblastoma
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
90 days
×
Clear all
NCT06514898
2026-04-03
MATCHPOINT
University of Florida
Phase 1
Active not recruiting
12 enrolled